Comprehensive review of semaglutide and non-arteritic anterior ischemic optic neuropathy synthesizes all available evidence on this potential GLP-1 drug eye safety concern.
Key findingComprehensive review of semaglutide and non-arteritic anterior ischemic optic neuropathy synthesizes
What the researchers found
Comprehensive review of semaglutide and non-arteritic anterior ischemic optic neuropathy synthesizes all available evidence on this potential GLP-1 drug eye safety concern.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Review covers the original matched cohort study, subsequent unselected population studies, and a meta-analysis of clinical trials examining the semaglutide-NAION association.
How the study worked
In publication.
Who was studied
Review covering semaglutide users across specialty clinic, population, and clinical trial data
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.
Acta ophthalmologica, 103(6), 615-621
Citation
Amini, Abdullah; Hamann, Steffen; Larsen, Michael. (2025). Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.. Acta ophthalmologica, 103(6), 615-621. https://doi.org/10.1111/aos.17473